Daniel C Terveen1, Steven R Sarkisian2, Steven D Vold3, Deepan Selvadurai4, Blake K Williamson5, Deborah G Ristvedt6, Adam R Bleeker1,7, Kavita Dhamdhere8,9, Jaime E Dickerson10,11. 1. Vance Thompson Vision, Sioux Falls, SD, USA. 2. Oklahoma Eye Surgeons, PLLC., Oklahoma City, OK, USA. 3. Vold Vision, Fayetteville, AR, USA. 4. Buffalo Ophthalmology, Williamsville, NY, USA. 5. The Williamson Eye Center., Baton Rouge, LA, USA. 6. Vance Thompson Vision, Alexandria, MN, USA. 7. University of South Dakota Sanford School of Medicine, Sioux Falls, SD, USA. 8. Sight Sciences, Inc., Menlo Park, CA, USA. 9. Mahatma Gandhi Medical College and Research Center, Wardha, India. 10. Sight Sciences, Inc., Menlo Park, CA, USA. jaime.dickerson@unthsc.edu. 11. North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, TX, USA. jaime.dickerson@unthsc.edu.
Abstract
PURPOSE: Evaluate effectiveness and safety outcomes for patients treated with canaloplasty and trabeculotomy previously treated with a trabecular microbypass stent (TBS). METHODS: Retrospective, multicenter, IRB approved study. Patients treated with TBS (iStent/iStent inject, Glaukos) and subsequently with OMNI surgical system (OSS) (Sight Sciences). From 5 practices in 5 US states. Open-angle glaucoma (OAG), minimum 3 months follow-up after OSS surgery, Pre-OSS IOP ≥ 17 mmHg on ≥ 1 medication. No glaucoma procedures between TBS and OSS. ENDPOINTS: proportion with ≥ 20% reduction in IOP, IOP between 6 and 18 mmHg, mean IOP, change in IOP, mean number of medications. Adverse events and secondary surgical interventions (SSI). Mann-Whitney rank sum test compared pre-OSS IOP and medications with follow-up. RESULTS: Twenty seven patients. Average age (SD) 72.2 (10.8), 22/27 primary OAG (82%), mean MD - 6.2 (7.0) dB. Mean IOP before OSS 22.3 (4.3) mmHg on 2.2 (1.3) medications. At last follow-up (mean 11 months) IOP was 17.2 mmHg on 1.8 medications, - 5.1 mmHg (- 23%, p < .001), - 0.4 meds (- 18%, p = .193); ≥ 20% IOP reduction (41%), IOP ≤ 18 (56%). Adverse events were non-serious. Hyphema > 1 mm (3, 11%), BCVA decrease (4, 15%), IOP spike (2, 7%). SSI (4, 15%) had higher pre-OSS IOP (23.4 mmHg) and worse MD (- 9.6 dB). CONCLUSION: Patients uncontrolled by medication and a prior TBS would once have been candidates for trabeculectomy and tube shunts. OSS offered a minimally invasive option that provided IOP control and avoidance of traditional surgery for the majority over follow-up averaging 11 months and up to 42 months.
PURPOSE: Evaluate effectiveness and safety outcomes for patients treated with canaloplasty and trabeculotomy previously treated with a trabecular microbypass stent (TBS). METHODS: Retrospective, multicenter, IRB approved study. Patients treated with TBS (iStent/iStent inject, Glaukos) and subsequently with OMNI surgical system (OSS) (Sight Sciences). From 5 practices in 5 US states. Open-angle glaucoma (OAG), minimum 3 months follow-up after OSS surgery, Pre-OSS IOP ≥ 17 mmHg on ≥ 1 medication. No glaucoma procedures between TBS and OSS. ENDPOINTS: proportion with ≥ 20% reduction in IOP, IOP between 6 and 18 mmHg, mean IOP, change in IOP, mean number of medications. Adverse events and secondary surgical interventions (SSI). Mann-Whitney rank sum test compared pre-OSS IOP and medications with follow-up. RESULTS: Twenty seven patients. Average age (SD) 72.2 (10.8), 22/27 primary OAG (82%), mean MD - 6.2 (7.0) dB. Mean IOP before OSS 22.3 (4.3) mmHg on 2.2 (1.3) medications. At last follow-up (mean 11 months) IOP was 17.2 mmHg on 1.8 medications, - 5.1 mmHg (- 23%, p < .001), - 0.4 meds (- 18%, p = .193); ≥ 20% IOP reduction (41%), IOP ≤ 18 (56%). Adverse events were non-serious. Hyphema > 1 mm (3, 11%), BCVA decrease (4, 15%), IOP spike (2, 7%). SSI (4, 15%) had higher pre-OSS IOP (23.4 mmHg) and worse MD (- 9.6 dB). CONCLUSION: Patients uncontrolled by medication and a prior TBS would once have been candidates for trabeculectomy and tube shunts. OSS offered a minimally invasive option that provided IOP control and avoidance of traditional surgery for the majority over follow-up averaging 11 months and up to 42 months.
Authors: George L Spaeth; João França Lopes; Anna K Junk; Adriana Paula Grigorian; Jeffrey Henderer Journal: Surv Ophthalmol Date: 2006 Jul-Aug Impact factor: 6.048
Authors: Mildred M G Olivier; Oluwatosin U Smith; Clarisse C Croteau-Chonka; Brian L VanderBeek; Maureen G Maguire; Flora Lum; Danielle Fujino; Scott P Kelly; William L Rich; Eydie G Miller-Ellis Journal: Ophthalmology Date: 2021-02-15 Impact factor: 12.079
Authors: Steven J Gedde; Kateki Vinod; Martha M Wright; Kelly W Muir; John T Lind; Philip P Chen; Tianjing Li; Steven L Mansberger Journal: Ophthalmology Date: 2020-11-12 Impact factor: 14.277
Authors: Shuang-An Yang; William Mitchell; Nathan Hall; Tobias Elze; Alice C Lorch; Joan W Miller; Nazlee Zebardast Journal: Ophthalmol Glaucoma Date: 2021-04-06
Authors: Mark J Gallardo; Steven R Sarkisian; Steven D Vold; Inder Paul Singh; Brian E Flowers; Anita Campbell; Kavita Dhamdhere; Thomas W Samuelson Journal: Clin Ophthalmol Date: 2021-02-10